Search

Objective To study the clinical effect on memantine combined olanzapine to treat the behavioral and psy chological symptoms of patients with Alzheimer′s disease. Methods According to random number table,120 cases of the behavioral and psychological symptoms patients with Alzheimer′s disease from April 2013 to December 2014 in Department of Geriatrics,the Mental Health center of Chongqing were divided into three groups,memantine treatment group(group A),olanzapine treatment group(group B),olanzapine combined memantine treatment group(group C),40 cases in each group. Before the treatment and at2,4,8,12 weeks during therapy,the behavioral pathology in Alzheimer′s disease rating scale(BEHAVE-AD) and Montreal cognitive assessment(MOCA)were used to evaluate curative effect,treatment emergent symptom scale(TESS)to evaluate drug adverse reactions. Results The BEHAVE-AD score in among three groups at 2,4,8,12 weeks during therapy were lower than those before the treatment,the differences were statistically significant(P< 0.05);at 2,4,8,12 weeks during therapy,the reducing score rate of BEHAVE-AD score in group A compared with group B,the differences were statistically significant(P<0.05). The MOCA score in group A,C at 12 weeks during therapy compared with that before the treatment,the differences were statistically significant(P<0.05),but group B was no statistically significant(P>0.05); The MOCA score in group A at 12 weeks during therapy compared with group C,the difference was no statistically significant(P>0.05).The incidence of adverse reactions in group A,C were obviously lower than group B,the differences were statistically significant(P<0.05);but group A compared with group C,the difference was no statistically significant(P > 0. 05). Conclusion Treatments by memantine combined olanzapine can quickly and effectively control the behavioral and psychological symptoms of patients with Alzheimer ′s disease,improve cognitive function and have less adverse reaction. [ABSTRACT FROM AUTHOR]

目的：评价丙戊酸钠联合奥氮平对阿尔茨海默病患者精神障碍的治疗作用。方法选取2010年5月至2016年1月该院收治的58例阿尔茨海默病患者作为研究对象，并将其分为对照组和观察组，各29例。观察组患者采用丙戊酸钠联合奥氮平进行治疗，对照组单用奥氮平进行治疗，采用双盲试验治疗2周后，观察两组的治疗效果。通过简明精神病评定量表（BPRS）对两组患者精神症状进行评分，并进行对比分析。结果第1周末，观察组的总有效率为75.86%（22/29），对照组的总有效率为44.83%（13/29），二者比较，差异有统计学意义（P＜0.05）。观察组患者治疗第1、2周末BPRS评分与治疗前比较，差异均有统计学意义（P＜0.05）；对照组在治疗第2周末与治疗前比较，差异有统计学意义（P＜0.05）。结论丙戊酸钠联合奥氮平能更好、更快地控制阿尔茨海默病患者的精神症状，值得临床推广。 [ABSTRACT FROM AUTHOR]

Objective To contrastively observe the clinical effects of different methods in treating the psychological and behavioral symptoms in the patients with Alzheimer′s disease (AD) to provide the reference for the clinical treatment. Methods 138 patients with AD in our hospital from February 2014 to February 2015 were selected as the research subjects and randomly divided into the group A, B and C, 46 cases in each group. The group A adopted the antipsychotic drug olanzapine treatment, the group B adopted the donepezil treatment and the group C was given the combined therapy of olanzapine and donepezil. The clinical effect, scores of dementia pathological behaviors and adverse reactions, and family members′ satisfaction on treatment were performed the contrastive analysis. Results There were no statistical differences between the group A and B in the aspects of clinical effect, scores of dementia pathological behaviors and adverse reactions, and family members′ satisfaction on treatment (P>0.05); but the clinical effect and the family members′total satisfaction on treatment in the group C were significantly higher than those in the group A and B group, while the scores of dementia pathological behaviors and the adverse reactions were lower than those in the group A and B, the differences were statistically significant (P<0.05). Conclusion Adopting the combined therapy of antipsychotic drug olanzapine and donepezi for treating the mental behavior symptoms of AD patients can significantly improve the clinical treatment effect and family members′satisfaction on treatment, has higher safety and deserves to be clinically promoted and applied. [ABSTRACT FROM AUTHOR]